Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (281-290 of 320) with videos related to

Pageof 32
Sort By:
JAMA|August 29, 2017
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular RiskBrian A Ference, John J P Kastelein, Henry N Ginsberg, et al.
Atherosclerosis|September 6, 2016
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR), Alberico L Catapano, Ian Graham, et al.
Atherosclerosis|August 16, 2011
Hypocholesterolemia, foam cell accumulation, but no atherosclerosis in mice lacking ABC-transporter A1 and scavenger receptor BIYing Zhao, Marieke Pennings, Carlos L J Vrins, et al.
Kardiologia Polska|December 3, 2016
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]Alberico L Catapano, Ian Graham, Guy De Backer, et al.
JAMA|January 30, 2019
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart DiseaseBrian A Ference, John J P Kastelein, Kausik K Ray, et al.
European Heart Journal|October 23, 2010
Lipoprotein(a) as a cardiovascular risk factor: current statusBørge G Nordestgaard, M John Chapman, Kausik Ray, et al.
European Heart Journal|April 29, 2016
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
European Heart Journal|May 3, 2011
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementM John Chapman, Henry N Ginsberg, Pierre Amarenco, et al.
Archives of Cardiovascular Diseases|November 29, 2021
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA)Vincent Durlach, Dominique Bonnefont-Rousselot, Franck Boccara, et al.
Circulation|November 12, 2019
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES TrialAmy Damask, P Gabriel Steg, Gregory G Schwartz, et al.
Pageof 32

Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
JAMA|August 29, 2017
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular RiskBrian A Ference, John J P Kastelein, Henry N Ginsberg, et al.
Atherosclerosis|September 6, 2016
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR), Alberico L Catapano, Ian Graham, et al.
Atherosclerosis|August 16, 2011
Hypocholesterolemia, foam cell accumulation, but no atherosclerosis in mice lacking ABC-transporter A1 and scavenger receptor BIYing Zhao, Marieke Pennings, Carlos L J Vrins, et al.
Kardiologia Polska|December 3, 2016
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]Alberico L Catapano, Ian Graham, Guy De Backer, et al.
JAMA|January 30, 2019
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart DiseaseBrian A Ference, John J P Kastelein, Kausik K Ray, et al.
European Heart Journal|October 23, 2010
Lipoprotein(a) as a cardiovascular risk factor: current statusBørge G Nordestgaard, M John Chapman, Kausik Ray, et al.
European Heart Journal|April 29, 2016
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
European Heart Journal|May 3, 2011
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementM John Chapman, Henry N Ginsberg, Pierre Amarenco, et al.
Archives of Cardiovascular Diseases|November 29, 2021
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA)Vincent Durlach, Dominique Bonnefont-Rousselot, Franck Boccara, et al.
Circulation|November 12, 2019
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES TrialAmy Damask, P Gabriel Steg, Gregory G Schwartz, et al.
Pageof 32